Evidence map›Paper›PMID 41782871›Full record

ArticleFrontiers in immunology2026

ctDNA guided management of POLE mutant GI malignancies promotes exceptional responses and prolonged survival to immunotherapy.

Umair Mahmood, Chetan Bhan, Charles Imber, Jamie Murphy, Krish Menon, Tara D Barwick, Zahir Amin, Khurum Khan

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Umair MahmoodDepartment of Gastrointestinal Oncology, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Chetan BhanCleveland Clinic London, London, United Kingdom.
Charles ImberCleveland Clinic London, London, United Kingdom.
Jamie MurphyCleveland Clinic London, London, United Kingdom.
Krish MenonCleveland Clinic London, London, United Kingdom.
Tara D BarwickImperial College Healthcare NHS Trust, London, United Kingdom.
Zahir AminThe London Clinic, London, United Kingdom.
Khurum KhanDepartment of Gastrointestinal Oncology, University College London Hospitals NHS Foundation Trust, London, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with unresectable Gastrointestinal cancers (GI) including advanced colorectal cancer (CRC) and gall bladder cancer (GBC) have limited treatment options. Treatment with chemotherapy is associated with limited success resulting from therapeutic resistance. Immune checkpoint inhibitors are effective for a subset of metastatic CRC (5% with MSI-H status) and up to 30% of patients with GBC. Therefore, there is an urgent unmet need to discover new predictive biomarkers to aid patient selection for ICIs with a demonstrated clinical value in a challenging patient population. We highlight the utility of a liquid biopsy approach to aid selection of GI cancer patients harbouring rare

Indexed as

Biomarkers, TumorCirculating Tumor DNADNA Polymerase IIGastrointestinal NeoplasmsImmunotherapyPoly-ADP-Ribose Binding ProteinsHumansImmune Checkpoint InhibitorsLiquid BiopsyMutationTreatment OutcomeBiomarkers, TumorCirculating Tumor DNADNA Polymerase IIImmune Checkpoint InhibitorsPOLE protein, humanPoly-ADP-Ribose Binding Proteinscolorectal cancerctDNAgall bladder cancerimmunotherapypole

Identifiers

PMID41782871
PMCPMC12953476

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.